Who is sponsoring B-HIVE?

B-HIVE is sponsored by University of California, San Francisco.

What condition does B-HIVE study?

B-HIVE studies Dyslipidemia, Cardiovascular Disease.

What drugs are being tested in B-HIVE?

Interventions: Bococizumab, Placebo.

What is the status of B-HIVE?

B-HIVE is currently TERMINATED.

Last reviewed 2019-06-17 · How we verify

Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects

NCT02524106 Phase 3 TERMINATED Results posted

B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 3
Status	TERMINATED
Enrolment	11
Start date	2016-08
Completion	2017-11

Conditions

Dyslipidemia
Cardiovascular Disease

Interventions

Bococizumab
Placebo

Primary outcomes

Change of LDL-C From Baseline to Week 12 — week 12
The primary endpoint for the study is the percent change from baseline in fasting LDL-C at week 12.

Countries

United States